In Vivo Biomarker Services

In vivo PK/PD studies are essential for determining the optimal dose, route of administration, and dosing schedule for a drug by analyzing the relationship between drug exposure and pharmacodynamic effects. Biomarker studies are necessary to validate biomarkers that can be used to monitor drug efficacy, predict treatment response, or identify patients who are most likely to benefit from a particular treatment. These data sets are critical for the regulatory approval of a drug.

We offer PK/PD and biomarker studies for a broad range of > 100 oncology preclinical models in mice and rats.

  • Cell line based syngeneic and xenogeneic models
  • Solid and hematological tumor models
  • Subcutaneous and orthotopic models (breast, brain, pancreas, liver, kidney)


We have established a broad panel of assays for human and mouse targets. A tumor-infiltrating lymphocyte (TIL) panel comprised of over 15 markers for systematic evaluation of TILs in mouse models. Assays for major populations of lymphocytes, macrophages, NK cells, and B cells are available. Protocols were optimized on mouse spleen and used to profile 15 different syngeneic mouse models (data on immune cell infiltration status of syngeneic mouse models is available for customers).

Read more: In vivo pharmacology–oncology platform